Targeted therapy for prostate cancer metastases to bone


    loading  Checking for direct PDF access through Ovid

Abstract

A large, randomized, phase III study has shown that denosumab, a monoclonal antibody targeting RANK ligand, is more effective than zoledronic acid for preventing skeletal morbidity in castration-resistant prostate cancer. Although denosumab is convenient to administer and well tolerated, its use is likely to be limited by economic considerations.

    loading  Loading Related Articles